Effect of Statins, Angiotensin-Converting Enzyme Inhibitors, and Beta Blockers on Survival in Patients ≥65 Years of Age With Heart Failure and Preserved Left Ventricular Systolic Function

American Journal of Cardiology

Volumn 101, Issue 2, 2008, Pages 217-222

  Shah, Rahman ^a,b   Wang, Yung ^a,c   Foody, JoAnne M ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c QUALIDIGM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DATABASES, FACTUAL; DIAGNOSIS-RELATED GROUPS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICAID; MEDICARE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; SYSTOLE; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 37549001362     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.08.050     Document Type: Article

References (25)

1. Ray J.G., Gong Y., Sykora K., and Tu J.V. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165 (2005) 62-67
2. Horwich T., MacLellan W., and Fonarow G. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
3. Go A.S., Lee W.Y., Yang J., Lo J.C., and Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296 (2006) 2105-2111
4. Foody J.M., Shah R., Galusha D., Masoudi F.A., Havranek E.P., and Krumholz H.M. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113 (2006) 1086-1092
5. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
6. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
7. Foody J.M., Farrell M.H., and Krumholz H.M. β-Blocker therapy in heart failure: scientific review. JAMA 287 (2002) 883-889
8. Philbin E.F., and Rocco J.T.A. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 134 (1997) 188-195
9. Fukuta H., Sane D.C., Brucks S., and Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005) 357-363
10. Aronow W.S., Ahn P.C., and Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 80 (1997) 207-209
11. Havranek E.P., Masoudi F.A., Westfall K.A., Wolfe P., Ordin D.L., and Krumholz H.M. Spectrum of heart failure in older patients: results from the national heart failure project. Am Heart J 143 (2002) 412-417
12. Marciniak T.A., Ellerbeck E.F., and Radford M.J. Improving the quality of care for Medicare patients with acute myocardial infarction; results from the Cooperative Cardiovascular Project. JAMA 279 (1998) 1351-1357
13. Fleming C., Fisher E.S., Chang C.H., Bubolz T.A., and Malenka D.J. Studying outcomes and hospital utilization in the elderly: the advantages of a merged data base for Medicare and Veterans Affairs hospitals. Medical Care 30 (1992) 377-391
14. Kenward K.P. The scope of the data available in the AMA's Physician Masterfile. Am J Public Health 86 (1996) 1481-1482
15. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
16. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., Wen J., and Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
17. Aronow W.S., and Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 71 (1993) 602-604
18. Dauterman K.W., Go A.S., Rowell R., Gebretsadik T., Gettner S., and Massie B.M. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail (2001) 221-228
19. Carson P., Johnson G., Fletcher R., and Cohn J. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol 27 (1996) 642-649
20. Eriksson S.V., Kjekshus J., Offstad J., and Swedberg K. Patient characteristics in cases of chronic severe heart failure with different degrees of left ventricular systolic dysfunction. Cardiology 85 (1994) 137-144
21. Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J., and on behalf of P.E.P.C.H.F.I. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 (2006) 2338-2345
22. Teo K., Yusuf S., Sleight P., Anderson C., Mookadam F., Ramos B., Hilbrich L., Pogue J., Schumacher H., and ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
23. Andersson B., Caidahl K., di Lenarda A., Warren S.E., Goss F., Waldenstrom A., Persson S., Wallentin I., Hjalmarson A., and Waagstein F. Changes in early and late diastolic filling patterns induced by long-term adrenergic β-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 94 (1996) 673-682
24. Shinozaki T., Watanabe J., and Kikuchi J. Rationale, design, and organization of the diastolic heart failure assessment study in Tohoku District (DIAST). Circulation 68 (2004) 660-664
25. Shibata M.C., Flather M.D., and Bohm M. Study of the effects of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure (SENIORS). Int J Cardiol 86 (2002) 77-85